Masimo Surges 6% on Preliminary Results Announcement
Masimo Surges 6% on Preliminary Results Announcement

Masimo Surges 6% on Preliminary Results Announcement

Jan. 10, 2024, 7:11 p.m., readers: 11

Masimo (NASDAQ:MASI) revealed its revenue projection for 2024, anticipating it to be between $2.05 billion and $2.17 billion. This forecast surpasses the consensus estimate of $2.09 billion at the midpoint. Additionally, the company expects its adjusted earnings per share (EPS) for the same year to range from $3.44 to $3.60, which is higher than the anticipated $3.08. Following this announcement, MASI's stock surged more than 6% today. The company also shared preliminary results for the fourth quarter, expecting revenue to fall between $541 million and $551 million, which is higher than the Street's estimate of $537 million.


About NASDAQ: MASI

M asimo Corporation develops, manufactures, and markets noninvasive monitoring technologies and hospital automation solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry. It also provides Masimo rainbow SET platform that includes rainbow SET Pulse CO-Oximetry products that noninvasively monitor hemoglobin species, including oxygen saturation, pulse rate, perfusion index, pleth variability index, and respiration rate from the pleth; noninvasively monitor hemoglobin concentration, and carboxyhemoglobin and methemoglobin;

Price: 131.06
Market cap: 6.9 billion USD
Eps: 1.62
P/e ratio: 80.90
Terminal Research: MASI